- Synaffix to provide access to proprietary ADC technologies (GlycoConnect™, HydraSpace™ and exatecan-based SYNtecan E™ linker payload)
- Emergence Therapeutics obtains the rights to develop multiple ADCs against undisclosed targets to strengthen its ADC portfolio
- Emergence Therapeutics becomes the 10th company to license the Synaffix ADC technology platform in a deal with a total potential value of up to $360 millionplus royalties on business sales
AMSTERDAM, September 6, 2022 /PRNewswire/ — Synaffix BV (Synaffix) and Emergence Therapeutics AG (“Emergence”) (“the Companies”) today announce that the Companies have entered into a license agreement for up to $360 millionproviding emergency access on a target-specific basis to Synaffix’s proprietary antibody conjugate (ADC) technologies comprising GlycoConnect™ linker payload, HydraSpace™ and SYNtecan E™.
Under the terms of the agreement, Synaffix will be eligible to receive up to $360 million in advance and milestone payments plus royalties on commercial sales. The first program will begin upon signing, with the option to expand the collaboration to additional targets. The deal is the result of positive proof-of-concept data following a successful initial discovery research collaboration between the companies.
Emergency will be responsible for the research, development, manufacturing and commercialization of ADCs. Synaffix will be responsible for manufacturing components that are specifically related to its proprietary technologies.
Jack Elands, CEO of Emergence Therapeutics, commented: “This transaction demonstrates our commitment to developing our portfolio of first-in-class and/or best-in-class ADCs. Beyond our leading ETx-22 program, a next-generation Nectin-4 ADC, we are actively advancing the other programs to develop treatments for high unmet need cancers. We are impressed with the Synaffix technology and are pleased to select it as a key component to accelerate our ADC portfolio.”
Peter van de SandeCEO of Synaffix, said: “This marks an important milestone for Synaffix as this is the 10the ADC developer who licensed our innovative ADC technology to develop proprietary ADCs for his own pipeline. By consolidating all core technologies within Synaffix, we have repeatedly enabled the development of best-in-class and first-in-class ADCs under a single technology license agreement. We are delighted that Emergence has selected Synaffix as their long-term ADC technology partner and look forward to working closely with Emergence as they build their pipeline of ADC candidates.”
About Synafix B.V.
Synaffix BV is a biotechnology company that enables ADC product candidates to use its site-specific and clinical-stage ADC technology platform. In addition to GlycoConnect™ and HydraSpace™ technology, the toxSYN™ linker payload platform completes a fully complementary technology platform that enables any company with an antibody to develop best-in-class ADC products with a single license from Synaffix.
The Synaffix platform enables a fast timeline for the clinic due to the established supply chain of technology components. The granted patents covering Synaffix’s technology provide end-to-end protection of the manufacturing technology as well as the resulting products until at least 2035. Synaffix’s business model is the licensing of target-specific technology, as exemplified through its existing agreements with ADC. Therapeutics, Mersana Therapeutics, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, and Macrogenics.
Synaffix is backed by a top-tier European life sciences-focused syndicate of investors including Aravis, BioGeneration Ventures, BOM Capital and M Ventures.
For more information, visit www.synaffix.com.
About AG Emergency Therapeutics
Emergence Therapeutics is a European biopharmaceutical company developing novel antibody drug conjugates (ADCs) to treat high-need cancers. Its lead program combines a highly specific antibody with an optimized linker and payload technology to attack Nectin-4, an important target for a wide range of cancers that has been clinically validated as an ADC target by enfortumab vedotin, now approved for the treatment of urothelial cancers. by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Emergence Therapeutics is also actively developing a portfolio of first- or best-in-class new ADCs driven by therapeutic need. Emergence is supported by a network of the world’s leading experts in immuno-oncology and a leading international syndicate of investors. Emergence Therapeutics AG is based in Duisburg, Germany with a subsidiary in Marseille, France. For more information please visit:
www.emergenciatx.com
About Synaffix ADC Platform Technology
Synaffix’s proprietary ADC technology platform consists of GlycoConnect™, HydraSpace™ and toxSYN™ technologies. Both GlycoConnect™ and HydraSpace™ are clinical-stage technologies that enable best-in-class ADCs with significantly improved efficacy and tolerability.
GlycoConnect™ is a conjugation technology that exploits native antibody glycan for stable, site-specific payload binding and can be tailored to the DAR1, DAR2, or DAR4 formats. HydraSpace™ is a highly polar, compact spacer technology that is designed to further improve therapeutic index, particularly with hydrophobic payloads. toxSYN™ is a linker payload platform that encompasses key and validated MOAs for ADC product development, including SYNtecan E™ and SYNeamicin G™, among other linker payloads.
The combination of these three technologies provides developers with a “single” and easy-to-use ADC technology platform, allowing any antibody developer to develop their own proprietary ADC and any ADC developer to further expand their portfolio and position themselves competitive.
SOURCE Sinafix
